Science & Technology
Science and Technology
Science and Technology
Mon, January 26, 2009
Bio-Matrix Scientific Group, Inc. Featured in National Investment Newsletter
SAN DIEGO--([ BUSINESS WIRE ])--Bio-Matrix Scientific Group, Inc. (OTCBB:BMSN) today announced that it was recently the "featured stock of the month" in the KonLin Letter ([ www.KonLin.com ]; 631-744-8536), a New York-based investment newsletter published by KonLin Research & Analysis Corp. The KonLin Letter is recognized as one of the nation's premier low-priced stock investment publications. The newsletter specializes in low-priced stocks under $10 with a specific focus on emerging growth and special situations poised for substantial growth and price appreciation.
Bio-Matrix is a San Diego, California-based development-stage biotechnology company ([ www.BMSN.us ]) focusing on the cryogenic storage of stem cells and the commercialization of medical devices used in living tissue transfer and stem cell research. BMSN recently opened its Cryogenic Stem Cell Bank in the San Diego area.
According to Konrad Kuhn, editor and publisher of The KonLin Letter, "Bio-Matrix Scientific Group, Inc. provides the highest quality stem cell-related processing and cryogenics storage, along with the development of instruments and procedures that assist the medical industry's further expansion into quality of life issues. BMSN's state-of-the-art stem cell bank provides the adult population the opportunity to store their own stem cells from umbilical cord blood and peripheral blood. The Company anticipates expanding its services into tissue banking."
Kuhn pointed out that BMSN has developed "a full line of disposable stem cell extraction surgical tools (192 instruments) which can be used to extract, transfer, and reintroduce cells. Furthermore, BMSN plans to open a DNA-Genetic testing laboratory for the molecular-level detection of genes linked to specific human diseases."
About Bio-Matrix Scientific Group
Bio-Matrix Scientific Group Inc. is a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market. The company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation. Bio-Matrix' new 15,000 sq. ft. state-of-the-art facility, located in the heart of San Diego's biotechnology corridor, will house Bio-Matrix' two secure Cryogenic Stem Cell Bank, three research laboratories, aseptic cellular/tissue class 10,000/100 processing laboratory, hematology, microbiology and flow cytometry laboratories.
Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
